← Leaderboards
Nasia Safdar
Wm S. Middleton Memorial Veterans Hosp
$21,112,666
Attributed
$22,618,756
Total exposure
19
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,094,717 · 6
AHRQ$6,524,039 · 5
VA$0 · 8
By mechanism
R01$7,872,955 · 3
U19$5,483,873 · 2
U01$5,157,302 · 1
DP2$2,295,000 · 1
R18$1,465,386 · 1
R03$344,240 · 3
Top collaborators
- Ophelia Venturelli1 shared
Most similar at Wm S. Middleton Memorial Veterans Hosp
Same institution · by research overlap
- Dane B Cook$1,377,888
- Michael J. Falvo$0
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionSiteCostPathogenAntibioticsPreventHealthcareIncidenceMulti-Drug Resistant PathogenVeteransDiarrheaClostridium DifficileBaseAntimicrobial ResistancePreventionStructureCaringRandomizedResistanceInfection ControlCommunicable DiseasesInpatientsProgramsInnovation
Grant awards (50)
Dietary Fiber-Microbiome Interactions: Elucidating Mechanisms to Suppress Multi-Drug Resistant Organisms in the Human Gut$3,012,181
R01 · FY2025 · AI
BCCMA: Targeting Gut-Microbiome in Veterans Deployment related Gastrointestinal and Liver diseases; CMA5- Functional metagenomics in GWI-related gut dysfunction$0
I01 · FY2024 · VA · contact PI
Effect of Expanding Barrier Precautions for Reducing Clostridium difficile Acquisition in VA.$0
I01 · FY2024 · VA · contact PI
Identification of novel MDR antimicrobials from human microbiome symbioses$1,266,106
U19 · FY2023 · AI · contact PI
BCCMA: Targeting Gut-Microbiome in Veterans Deployment related Gastrointestinal and Liver diseases; CMA5- Functional metagenomics in GWI-related gut dysfunction$0
I01 · FY2023 · VA · contact PI
Effect of Expanding Barrier Precautions for Reducing Clostridium difficile Acquisition in VA.$0
I01 · FY2023 · VA · contact PI
Identification of novel MDR antimicrobials from human microbiome symbioses$1,060,230
U19 · FY2022 · AI · contact PI
Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients$1,022,090
U01 · FY2022 · AI · contact PI
Fluoroquinolone Restriction for the Prevention of C. difficile Infection (CDI)_the FIRST Trial.$498,021
R01 · FY2022 · HS · contact PI
Mentored Enhanced Implementation and Evaluation of National VA Mandates To Prevent The Spread Of C Difficile infection$0
I01 · FY2022 · VA · contact PI
Effect of Expanding Barrier Precautions for Reducing Clostridium difficile Acquisition in VA.$0
I01 · FY2022 · VA · contact PI
Identification of novel MDR antimicrobials from human microbiome symbioses$1,027,236
U19 · FY2021 · AI · contact PI
Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients$1,005,421
U01 · FY2021 · AI · contact PI
Fluoroquinolone Restriction for the Prevention of C. difficile Infection (CDI)_the FIRST Trial.$498,021
R01 · FY2021 · HS · contact PI
Efficacy of oral vancomycin prophylaxis for prevention of recurrent C. difficile infection$464,700
R01 · FY2021 · HS · contact PI
Effect of Expanding Barrier Precautions for Reducing Clostridium difficile Acquisition in VA.$0
I01 · FY2021 · VA · contact PI
Mentored Enhanced Implementation and Evaluation of National VA Mandates To Prevent The Spread Of C Difficile infection$0
I01 · FY2021 · VA · contact PI
Reducing VA Healthcare-Associated Infections through Antibiotic StEwardship (RAISE)$0
I50 · FY2021 · VA · contact PI
Building implementation science for VA healthcare associated infection prevention$0
I50 · FY2021 · VA · contact PI
Identification of novel MDR antimicrobials from human microbiome symbioses$1,115,616
U19 · FY2020 · AI · contact PI
Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients$1,001,192
U01 · FY2020 · AI · contact PI
Fluoroquinolone Restriction for the Prevention of C. difficile Infection (CDI)_the FIRST Trial.$498,021
R01 · FY2020 · HS · contact PI
Efficacy of oral vancomycin prophylaxis for prevention of recurrent C. difficile infection$474,458
R01 · FY2020 · HS · contact PI
Mentored Enhanced Implementation and Evaluation of National VA Mandates To Prevent The Spread Of C Difficile infection$0
I01 · FY2020 · VA · contact PI
Reducing VA Healthcare-Associated Infections through Antibiotic StEwardship (RAISE)$0
I50 · FY2020 · VA · contact PI
Identification of novel MDR antimicrobials from human microbiome symbioses$1,014,685
U19 · FY2019 · AI · contact PI
Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients$1,002,166
U01 · FY2019 · AI · contact PI
Fluoroquinolone Restriction for the Prevention of C. difficile Infection (CDI)_the FIRST Trial.$490,371
R01 · FY2019 · HS · contact PI
Efficacy of oral vancomycin prophylaxis for prevention of recurrent C. difficile infection$481,278
R01 · FY2019 · HS · contact PI
Examining the gut microbiota in Veterans with Gulf War Illness$0
I21 · FY2019 · VA · contact PI
Modelling applications and systems engineering to reduce infections_the MASTERI study.$2,295,000
DP2 · FY2018 · AI · contact PI
Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients$1,126,433
U01 · FY2018 · AI · contact PI
Efficacy of oral vancomycin prophylaxis for prevention of recurrent C. difficile infection$488,150
R01 · FY2018 · HS · contact PI
Fluoroquinolone Restriction for the Prevention of C. difficile Infection (CDI)_the FIRST Trial.$472,103
R01 · FY2018 · HS · contact PI
Mentored Enhanced Implementation and Evaluation of National VA Mandates To Prevent The Spread Of C Difficile infection$0
I01 · FY2018 · VA · contact PI
Examining the gut microbiota in Veterans with Gulf War Illness$0
I21 · FY2018 · VA · contact PI
Efficacy of oral vancomycin prophylaxis for prevention of recurrent C. difficile infection$495,651
R01 · FY2017 · HS · contact PI
Implementation of Chlorhexidine Bathing to Reduce Healthcare-Associated Infections-the Icare study$487,856
R18 · FY2017 · HS · contact PI
The GRAFT study: Gut RecolonizAtion by Fecal Transplantation$100,000
R03 · FY2017 · HS · contact PI
Implementation of Chlorhexidine Bathing to Reduce Healthcare-Associated Infections-the Icare study$488,586
R18 · FY2016 · HS · contact PI
IMpact of PRObiotics for reducing infections in VEterans: The IMPROVE Study$0
I01 · FY2016 · VA · contact PI
Implementation of Chlorhexidine Bathing to Reduce Healthcare-Associated Infections-the Icare study$488,944
R18 · FY2015 · HS · contact PI
A systems engineering approach to reducing C. difficile infection$97,879
R03 · FY2015 · HS · contact PI
IMpact of PRObiotics for reducing infections in VEterans: The IMPROVE Study$0
I01 · FY2015 · VA · contact PI
Barriers and Facilitators for Clostridium difficile Bundle Implementation$0
I21 · FY2014 · VA · contact PI
IMpact of PRObiotics for reducing infections in VEterans: The IMPROVE Study$0
I01 · FY2014 · VA · contact PI
Probiotics to Improve Outcomes of Clostridium difficile$71,111
R03 · FY2013 · AG · contact PI
IMpact of PRObiotics for reducing infections in VEterans: The IMPROVE Study$0
I01 · FY2013 · VA · contact PI
Probiotics to Improve Outcomes of Clostridium difficile$75,250
R03 · FY2012 · AG · contact PI
IMpact of PRObiotics for reducing infections in VEterans: The IMPROVE Study$0
I01 · FY2012 · VA · contact PI